About aTyr Pharma (NASDAQ:LIFE)
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:LIFE
CUSIP53217V10
Phone858-731-8389
Debt
Debt-to-Equity Ratio0.23%
Current Ratio8.37%
Quick Ratio8.37%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.16 per share
Price / Book1.11
Profitability
EPS (Most Recent Fiscal Year)($1.87)
Net Income$-48,200,000.00
Net MarginsN/A
Return on Equity-84.85%
Return on Assets-62.00%
Miscellaneous
Employees65
Outstanding Shares29,800,000
aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma, Inc. (NASDAQ:LIFE) posted its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.50) by $0.07. View aTyr Pharma's Earnings History.
When is aTyr Pharma's next earnings date?
What price target have analysts set for LIFE?
3 brokers have issued twelve-month price targets for aTyr Pharma's stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate aTyr Pharma's stock price to reach $5.50 in the next year. View Analyst Ratings for aTyr Pharma.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include Pluristem Therapeutics (PSTI), Organovo (ONVO), Lorus Therapeutics (APTO), Eiger Biopharmaceuticals (EIGR), Aevi Genomic Medicine (GNMX), Curis (CRIS), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), Genocea Biosciences (GNCA), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Proteon Therapeutics (PRTO), Vaxart (VXRT), Vical (VICL), Microbot Medical (MBOT), Neuralstem (CUR) and Oncobiologics (ONS).
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 46)
- Dr. Paul R. Schimmel, Founder & Director (Age 77)
- Dr. David J. King, Chief Scientific Officer (Age 59)
- Dr. John D. Mendlein, Strategic Advisor & Director (Age 58)
- Dr. Sanuj K. Ravindran, Bus. Advisor (Age 46)
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Has aTyr Pharma been receiving favorable news coverage?
News headlines about LIFE stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. aTyr Pharma earned a media sentiment score of 0.13 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.88 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of aTyr Pharma?
Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of LIFE stock can currently be purchased for approximately $2.40.
How big of a company is aTyr Pharma?
aTyr Pharma has a market capitalization of $73 million. The biotechnology company earns $-48,200,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. aTyr Pharma employs 65 workers across the globe.
How can I contact aTyr Pharma?
aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]
MarketBeat Community Rating for aTyr Pharma (LIFE)
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
aTyr Pharma (NASDAQ:LIFE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for aTyr Pharma in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 129.17%. The high price target for LIFE is $7.00 and the low price target for LIFE is $4.00. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.25 | 2.25 |
| Ratings Breakdown: | 1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.50 | $5.50 | $5.00 | $4.4625 |
| Price Target Upside: | 129.17% upside | 57.14% upside | 78.57% upside | 59.38% upside |
aTyr Pharma (NASDAQ:LIFE) Consensus Price Target History
aTyr Pharma (NASDAQ:LIFE) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
aTyr Pharma (NASDAQ:LIFE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
aTyr Pharma (NASDAQ LIFE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 25.00%
Institutional Ownership Percentage: 58.81%
aTyr Pharma (NASDAQ LIFE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/8/2018 | Ashraf Amanullah | Insider | Sell | 1,402 | $3.40 | $4,766.80 | |  |
| 8/31/2017 | John Mendlein | CEO | Buy | 37,736 | $2.65 | $100,000.40 | | |
| 8/31/2017 | Paul Schimmel | Director | Buy | 94,336 | $2.65 | $249,990.40 | 40,440 | |
| 4/24/2017 | John Mendlein | CEO | Buy | 124 | $3.00 | $372.00 | 327,647 | |
| 4/20/2017 | John Mendlein | CEO | Buy | 2,552 | $3.00 | $7,656.00 | 325,971 | |
| 12/21/2016 | Paul Schimmel | Director | Buy | 25,000 | $2.28 | $57,000.00 | 40,440 | |
| 12/20/2016 | Ashraf Amanullah | VP | Buy | 11,000 | $2.25 | $24,750.00 | 11,000 | |
| 12/19/2016 | John Mendlein | CEO | Buy | 69,000 | $2.20 | $151,800.00 | | |
| 12/16/2016 | Paul Schimmel | Director | Buy | 50,000 | $2.48 | $124,000.00 | 40,440 | |
| 5/11/2016 | Grove Matsuoka | Insider | Buy | 12,412 | $3.04 | $37,732.48 | 2,412 | |
| 4/14/2016 | Paul Schimmel | Director | Buy | 66,219 | $4.18 | $276,795.42 | 53,012 | |
| 4/13/2016 | Paul Schimmel | Director | Buy | 9,835 | $3.85 | $37,864.75 | 20,412 | |
| 4/12/2016 | Paul Schimmel | Director | Buy | 9,127 | $3.71 | $33,861.17 | 20,412 | |
| 4/11/2016 | Paul Schimmel | Director | Buy | 32,659 | $3.57 | $116,592.63 | 214,931 | |
| 4/8/2016 | Paul Schimmel | Director | Buy | 85,000 | $3.22 | $273,700.00 | 187,572 | |
| 4/7/2016 | Paul Schimmel | Director | Buy | 40,000 | $3.19 | $127,600.00 | 102,572 | |
| 4/6/2016 | Paul Schimmel | Director | Buy | 25,000 | $3.20 | $80,000.00 | 62,572 | |
| 4/5/2016 | John Mendlein | CEO | Buy | 2,500 | $3.55 | $8,875.00 | 248,471 | |
| 4/5/2016 | Paul Schimmel | Director | Buy | 25,000 | $3.52 | $88,000.00 | 37,572 | |
| 5/12/2015 | James E Flynn | Insider | Buy | 50,000 | $14.00 | $700,000.00 | | |
| 5/12/2015 | Sofinnova Venture Partners Ix, | Major Shareholder | Buy | 320,000 | $14.00 | $4,480,000.00 | | |
| 5/29/2013 | David C Uprichard | Director | Sell | 2,010 | $74.04 | $148,820.40 | | |
| 5/28/2013 | John A Cottingham | Insider | Sell | 60,000 | $74.03 | $4,441,800.00 | | |
(Data available from 1/1/2013 forward)
aTyr Pharma (NASDAQ LIFE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Q1 2018 EPS Estimates for aTyr Pharma, Inc. (LIFE) Boosted by Analyst
www.americanbankingnews.com - April 20 at 7:10 AM |
| Analysts Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.39 Earnings Per Share
www.americanbankingnews.com - April 19 at 3:10 PM |
 | Eleven Biotherapeutics: Incredible Risk/Reward With A Catalyst Approaching
seekingalpha.com - April 19 at 9:03 AM |
| aTyr Pharma (LIFE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:42 PM |
| aTyr Pharma (LIFE) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 8:35 PM |
| Zacks Investment Research Lowers aTyr Pharma (LIFE) to Hold
www.americanbankingnews.com - April 9 at 6:58 PM |
| aTyr Pharma (LIFE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM |
| aTyr Pharma (LIFE) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 9 at 11:02 AM |
| aTyr Pharma (LIFE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 6 at 7:38 PM |
| Zacks: Analysts Anticipate aTyr Pharma Inc (LIFE) to Announce -$0.39 Earnings Per Share
www.americanbankingnews.com - April 2 at 5:20 PM |
| aTyr Pharma (LIFE) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 1:49 PM |
 | aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - March 26 at 9:27 AM |
| aTyr Pharma (LIFE) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - March 24 at 7:20 PM |
| Zacks Investment Research Upgrades aTyr Pharma (LIFE) to Buy
www.americanbankingnews.com - March 23 at 7:56 PM |
| William Blair Equities Analysts Lift Earnings Estimates for aTyr Pharma Inc (LIFE)
www.americanbankingnews.com - March 22 at 8:45 AM |
| aTyr Pharma Inc Expected to Earn Q1 2019 Earnings of ($0.37) Per Share (LIFE)
www.americanbankingnews.com - March 21 at 11:01 AM |
| Edited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMT
finance.yahoo.com - March 20 at 4:39 PM |
 | aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update
globenewswire.com - March 20 at 9:18 AM |
| aTyr Pharma, Inc. to Host Earnings Call
finance.yahoo.com - March 20 at 9:18 AM |
 | Are Big Pharma Using Corporate Tax Savings to Lower Drugs Costs?
www.zacks.com - March 10 at 9:08 AM |
| aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018
finance.yahoo.com - March 7 at 9:14 AM |
| aTyr Pharma (LIFE) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 7 at 2:14 AM |
| Contrasting aTyr Pharma (LIFE) and Oncomed Pharmaceuticals (OMED)
www.americanbankingnews.com - March 4 at 5:18 PM |
| aTyr Pharma to Present at Two Upcoming Investor Conferences in March
finance.yahoo.com - March 1 at 8:53 AM |
| aTyr Pharma Inc (LIFE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 1 at 5:30 AM |
| aTyr Pharma (LIFE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 24 at 9:48 PM |
| JPMorgan Chase & Co. Lowers aTyr Pharma (LIFE) to Underweight
www.americanbankingnews.com - February 14 at 10:38 AM |
| Zacks: Analysts Anticipate aTyr Pharma, Inc. (LIFE) Will Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - February 10 at 9:18 PM |
| Q1 2018 Earnings Forecast for aTyr Pharma, Inc. Issued By William Blair (LIFE)
www.americanbankingnews.com - February 8 at 9:18 AM |
| Achieve Life Sciences (ACHV) vs. aTyr Pharma (LIFE) Head-To-Head Analysis
www.americanbankingnews.com - February 5 at 11:14 PM |
| aTyr Pharma, Inc. (LIFE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 4 at 5:30 AM |
| Zacks: Analysts Expect aTyr Pharma, Inc. (LIFE) Will Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - January 24 at 9:24 PM |
| aTyr Pharma (LIFE) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - January 17 at 6:10 AM |
| aTyr Pharma, Inc. (LIFE) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 10 at 8:14 AM |
| Brokerages Anticipate aTyr Pharma, Inc. (LIFE) to Post -$0.43 Earnings Per Share
www.americanbankingnews.com - January 7 at 5:26 PM |
| aTyr Pharma (LIFE) versus Nektar Therapeutics (NKTR) Head-To-Head Review
www.americanbankingnews.com - January 5 at 9:16 PM |
| aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium - GlobeNewswire (press release)
globenewswire.com - December 23 at 5:23 AM |
| aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
finance.yahoo.com - December 21 at 9:19 AM |
| aTyr Pharma, Inc. (LIFE) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 16 at 8:46 AM |
| aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 9:24 AM |
| Zacks: Analysts Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.44 Earnings Per Share
www.americanbankingnews.com - December 4 at 3:14 PM |
| aTyr Pharma (LIFE) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 8:34 AM |
| aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc ... - GlobeNewswire (press release)
globenewswire.com - November 28 at 10:00 AM |
| aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
finance.yahoo.com - November 27 at 5:06 PM |
| aTyr Pharma, Inc. (LIFE) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 21 at 8:16 AM |
| aTyr Pharma, Inc. (LIFE) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 18 at 6:40 AM |
| FY2017 EPS Estimates for aTyr Pharma, Inc. Raised by William Blair (LIFE)
www.americanbankingnews.com - November 17 at 8:52 PM |
| Atyr Pharma reports 3Q loss
finance.yahoo.com - November 17 at 1:16 PM |
| aTyr Pharma, Inc. (LIFE) Posts Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - November 15 at 12:43 PM |
| aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - November 15 at 4:14 AM |
aTyr Pharma (NASDAQ:LIFE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
aTyr Pharma (NASDAQ:LIFE) Income Statement, Balance Sheet and Cash Flow Statement
aTyr Pharma (NASDAQ LIFE) Stock Chart for Saturday, April, 21, 2018
Loading chart…
